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Abstract
Introduction: Central retinal vein occlusion is one of the major causes of severe vision impairment
and blindness in adults.
Case presentation: We present a case of unilateral ischemic central retinal vein occlusion in a
54-year-old woman with history of uncontrolled hypertension and open angle glaucoma. Laboratory
tests including complete hypercoagulability and thrombotic workup were completed.
Conclusion: Our case illustrates an interesting presentation of unilateral ischemic central retinal
vein occlusion, where hypertension and glaucoma were thought to be the main risk factors. Close
follow up, tight blood pressure and glaucoma control are crucial to prevent similar scenario in the
fellow eye.
Introduction
Central retinal vein occlusion (CRVO) is one of the major
causes of severe vision impairment and blindness [1].
Thrombosis of the central retinal vein results in venous
stasis, leading to disc swelling, diffuse nerve fiber layer
and pre-retinal hemorrhage, and cotton wool spots that
create a dramatic appearance, often called “the blood and
thunder” fundus.
The prevalence of central retinal vein occlusion (CRVO)
is 0.1 to 0.7 percent in population-based studies [2].
A population-based study found a cumulative incidence of
0.5 percent over 15 years, with a prevalence of 1.3 percent
for people aged 65 years and older [3].
Occlusion or thrombosis of the central retinal vein is
associated with chronic glaucoma, atherosclerotic risk
factors (age, diabetes, and hypertension), hyperviscosity,
coagulopathy, andmigraine [3-6]. The causeof retinal vein
occlusion is often unknown.
While vision loss may be severe, the onset is typically
subacute, in contrast to the sudden visual loss typical of
central retinal artery occlusion. When venous stasis is
severe, infarction may occur due to slowed retinal blood
flow on the arterial side. In this setting, a relative afferent
papillary defect is often present.
We present an interesting case of unilateral ischemic
central retinal vein occlusion. We will discuss the risk
Page 1 of 4
(page number not for citation purposes)factors, the complications, and the management guide-
lines in CRVO.
Case presentation
A 54-year-old African American female with history of
uncontrolled hypertension and glaucoma presented to
the eye clinic with sudden vision loss in the right eye
upon awakening. She has been taking Clonidine 10 mg
oral twice daily and Latanoprost 1 drop in each eye twice
daily.
Vital signs upon presentation are summarized in Table 1.
Electrocardiogram showed sinus rhythm, and left ventri-
cular hypertrophy.
Ophthalmologic exam showed best corrected visual acuity
of hand motion in the right eye and 20/70 in the left eye.
Pupil exam showed sluggish right pupil with relative
afferent papillary defect, and a reactive pupil on the left.
Intraocular pressures were 19 mmHg in the right, and
11 mmHg in the left.
Slit lamp exam showed normal anterior segments with
open angles bilaterally.
Fundus examination of the right eye revealed cup to disk
ratio of 0.7, dilated and tortuous retinal veins, with
intraretinal hemorrhages especially in the peripapillary
region (Figure 1). Fundus examination of the left eye
revealed cup to disk ratio of 0.7, otherwise normal optic
disc and flat macula.
Differential diagnosis in the right eye included central
retinal vein occlusion (CRVO), ocular ischemic syndrome,
diabetic retinopathy, papilledema, and acute hypertensive
retinopathy (Figure 3).
Flourescein Angiogram of the right eye showed blocked
venous fluorescence from the retinal hemorrhages, exten-
sive areas of capillary non-perfusion, and vessel wall
staining. Patient was diagnosed with unilateral ischemic
central retinal vein occlusion in the right eye. Laboratory
tests including complete hypercoagulability and throm-
botic workup were completed (Tables 2, 3).
Patient was prescribed aspirin 81 mg daily. Amlodipine
10 mg, and Hydrochlorothiazide 25 mg were added to
achieve better blood pressure control. Timolol and
Brimonide eye drops were added to achieve better control
of the intraocular pressure.
Patient was advised to follow closely during the next
six months, including gonioscopy and undilated exam-
ination of the iris to check for neovascularization of the
iris/disc.
Table 1. Vital signs upon presentation are summarized in Table 1
Temperature 97.0 F
Respiratory rate 19 breath/min
Blood pressure 190/103 mmHg
Heart rate 64 bpm
Pain 0/10
Figure 1. Color Fundus photograph of the right eye showed
superficial opacification of the retina in the macular area in
combination with multiple dot-blot and flame-shaped
hemorrhages in all four quadrants (including the area nasally to
the optic nerve).
Figure 2. Color Fundus photograph of the left eye showed
normal optic disc, and flat macula (normal findings).
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CRVO has two types:
 Nonischemic (70%): which is characterized by vision
that is better than 20/200, 16% progress to nonperfused;
50% resolve completely without treatment; defined as
<10 disk diameter (DD) of capillary nonperfusion.
 Ischemic (30%): which is defined as more than 10 DD
of nonperfusion; patients are usually older and have
worse vision; 60% develop iris NV; up to 33% develop
neovascular glaucoma; 10% are combined with branch
retinal arterial occlusion (usually cilioretinal artery due
to low perfusion pressure of choroidal system) [7].
Central retinal vein occlusion is a disease of the old
population (age >50 years old). Major risk factors
are hypertension, diabetes, and atherosclerosis. Other
risk factors are glaucoma, syphilis, sarcoidosis, vasculitis,
increased intraorbital or intraocular pressure, hyphema,
hyperviscosity syndromes (multiple myeloma, Walden-
strom’s macroglobulinemia, and leukemia), high homo-
cysteine levels, sickle cell, and HIV [8].
Paul O’Mahoney et al. studied the relationship between
traditional atherosclerosis risk factors and retinal vein
occlusion (RVO). They systematically retrieved all studies
between 1985 and 2007 that compared cases with any
RVO with controls. They concluded that hypertension and
hyperlipidemia are common risk factors for RVO in adults,
a n dd i a b e t e sm e l l i t u si sl e s ss o .I tr e m a i n st ob e
determined whether lowering blood pressure and/or
serum lipids levels can improve visual acuity or the
complications of RVO [9].
Open-angle glaucoma is the most common local factor
predisposing to RVO as increased intraocular pressure
compromises retinal vein outflow and produces stasis
[10,11].
Figure 3. Flourescein Angiogram of the right eye showed
blocked venous fluorescence from the retinal hemorrhages,
extensive areas of capillary non-perfusion, and vessel wall
staining.
Figure 4. An example of acute hypertensive retinopathy,
which is one of the differentials for CRVO. Figures here are
showing arteriovenous nicking, copper wire arterial changes,
hemorrhages, cotton wool spots, disc edema bilaterally (Left
more than the right), and exudates that dominate in the
peripapillary area.
Table 2. Laboratory tests including hypercoagulability workup are
summarized in Table 2
Glucose 90
HgA1c 5.8
White blood cell count 9.8
Neutrophils 80%
Lymphocytes 14%
Monocytes 4.6%
Hemoglobin 15.0
Hematocrit 45.1
Platelets 282
MCV 84.3
RDW 14.6
Prothrombin time 12.5
INR 0.99
PTT LA 33 normal (Reference normal < 40)
ANA Negative
Rheumatoid factor Negative
ESR 10 (normal)
CRP 20 (normal)
Serum protein electrophoresis Normal
Lipid profile Normal
Hemoglobin electrophoresis Normal
VDRL Negative
FTA-ABS Negative
Table 3. Further hypercoagulability workup is summarized in Table 3
HIV Negative
Functional protein S assay Normal
Functional protein C assay Normal
Functional antithrombin III assay Normal
Antiphospholipid antibody titer 262 (reference range = 151-264)
Lupus anticoagulant Negative
Anticardiolipin antibody Negative
Homocysteine 11.5 (0-10) High
Folate level Normal
B12 level Normal
Creatinine 0.9 mg per deciliter
Factor V Leiden PCR assay Negative
Page 3 of 4
(page number not for citation purposes)
Cases Journal 2009, 2:7170 http://casesjournal.com/casesjournal/article/view/7170Every eye with CRVO is at risk for developing neovascular
glaucoma. Lowering intraocular pressure helps to improve
retinal circulation in an eye with CRVO [12], and there
is a 10% risk for development of BRVO or CRVO in the
fellow eye [13].
Risk factors for developing neovascular iris in patients with
CRVO are the amount of nonperfused retina, extent of
retinal hemorrhages, male sex, and central vein occlusion
of less than one month duration [14]. Visual acuity in
patients with CRVO at baseline is a strong predictor for the
development of INV/ANV, as is the amount of nonperfu-
sion seen by fluorescein angiogram [1].
The central vein occlusion study (CVOS) data did not
support the recommendation for prophylactic panretinal
photocoagulation (PRP). The CVOS found that early PRP
decreased the rate of iris neovascularization (INV);
however, the reduction was not statistically significant.
Moreover, the study showed that early PRP reduced, but
did not eliminate, the possibility of anterior-segment
neovascularization. The CVOS recommended close fol-
low-up of eyes with CRVO during the first 6 months
(including gonioscopy and undilated slit lamp examina-
tion of the iris) and prompt PRP of eyes in which
iris neovascularization (INV)/Angle neovascularization
(ANV) develops [14].
Although PRP was better than selective PRP or photo-
dynamic therapy (PDT) at determining INV and anterior
segment neovascularization regression, selective PRP or
PDT can also be safely used to manage anterior segment
neovascularization secondary to ischemic CRVO [15].
Conclusion
Our case illustrates an interesting presentation of uni-
lateral ischemic central retinal vein occlusion, where
hypertension and glaucoma were thought to be the main
risk factors. While many interventions for fixed visual loss
associated with CRVO have largely not proven to be
of benefit, our management focused on controlling
blood pressure and glaucoma as preventive measures to
protect the fellow eye. Meanwhile, close follow up was
emphasized to investigate for signs of iris/angle
neovascularization.
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